BioAge Labs Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.6%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$2.37next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly384.9MTarget: Sufficient to fund operations through 2029
Collaboration Revenue Quarterly2.8MTarget: Driven by Novartis FTE effort and milestones
BGE-102 hsCRP Reduction (Median % from Baseline) Annually8,600.0%Target: Maintain >80% reduction in Phase 2 trials
Watch Items
- QUELL-CV Phase 2 Proof-of-Concept Topline DataTrigger: Topline data release expected in H2 2026Action: Evaluate percent change in hsCRP and safety profile to support Phase 3 dose selection.
- First IND Filing for APJ Agonist ProgramTrigger: Filing target by year-end 2026Action: Monitor preclinical progress and regulatory submissions for the oral/injectable APJ obesity pipeline.
- BGE-102 Phase 1b/2a DME Proof-of-Concept Trial InitiationTrigger: Trial initiation planned for mid-2026Action: Track first patient dosed and subsequent clinical progress in diabetic macular edema.
Research as of 19 Jun 2026